These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

87 related articles for article (PubMed ID: 8377332)

  • 1. [The effect of concanavalin A-activated leukocytes on coagulation hemostasis in patients with ischemic heart disease].
    Liusov VA; Uteshev DV; Diukov IV
    Kardiologiia; 1993; 33(3):18-9. PubMed ID: 8377332
    [No Abstract]   [Full Text] [Related]  

  • 2. Lymphokines and thrombosis. II. Procoagulant activity produced by human lymphocytes stimulated with concanavalin A (con-A).
    Coeugniet E; Bendixen G
    Acta Allergol; 1976 Apr; 31(2):107-15. PubMed ID: 947136
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [The effect of contrast baths on the hemostatic function of patients with ischemic heart disease].
    Sorokina EI; Ali O
    Vopr Kurortol Fizioter Lech Fiz Kult; 1998; (3):26-8. PubMed ID: 9771141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Thrombocytic-vascular hemostasis at rest and under physical loading in patients with ischemic heart disease].
    Mingazetdinova LN; Shaĭmukhametova LT
    Kardiologiia; 1993; 33(3):12-4. PubMed ID: 8377329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Preoperative plasma- and thrombocytapheresis in patients with ischemic heart disease].
    Shilov VV; Skorik VI; Borisov IA; Soroka VV; Ivashchenko AI; Gusev SV; Bozhenko SA; Sudus AV
    Vestn Khir Im I I Grek; 1995; 154(2):77-81. PubMed ID: 8540196
    [No Abstract]   [Full Text] [Related]  

  • 6. [Connection of endothelial dysfunction and level of blood leukocytes with clinical course of stable angina pectoris in patients with ischemic heart disease].
    Lyzohub VH; Savchenko OV; Bondarchuk OM; Dykukha IS; Voloshyna OO; Bohdan TV; Koval'chuk SM; Moshkovs'ka IuO
    Lik Sprava; 2008; (1-2):67-71. PubMed ID: 18822846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Soluble tissue factor and tissue factor pathway inhibitor in cardiovascular disease.
    Toschi V
    J Thromb Haemost; 2007 Mar; 5(3):472-4. PubMed ID: 17319902
    [No Abstract]   [Full Text] [Related]  

  • 8. Tissue factor, tissue factor pathway inhibitor and cytoadhesive molecules in patients with an acute coronary syndrome.
    Malý M; Vojácek J; Hrabos V; Kvasnicka J; Salaj P; Durdil V
    Physiol Res; 2003; 52(6):719-28. PubMed ID: 14640893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [The effect of plasmapheresis and antianginal therapy on lipid metabolism, eicosanoids and the thrombocytic link of hemostasis in patients with ischemic heart disease].
    Topchiĭ II; Volkov VI; Kidon' VP; Kravchenko IG
    Lik Sprava; 1993; (2-3):50-3. PubMed ID: 8191735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of physical load on the platelet function and ultrastructure in patients with ischemic heart disease.
    Oral I; Hrcková Y; Frysák Z; Kamarád V
    Acta Univ Palacki Olomuc Fac Med; 1992; 133():39-41. PubMed ID: 1344596
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The importance of von Willebrand factor level and heart rate changes in acute coronary syndromes: a comparison with chronic ischemic conditions.
    Heper G; Bayraktaroğlu M
    Angiology; 2003; 54(3):287-99. PubMed ID: 12785021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Behavior of plasmatic coagulation factors in various stages of coronary sclerosis, confirmed by coronarography].
    Nelius D; Parsi RA; Stürmer U
    Z Alternsforsch; 1973; 27(3):277-82. PubMed ID: 4771228
    [No Abstract]   [Full Text] [Related]  

  • 13. [The dietetic aspects of the treatment of patients with ischemic heart disease].
    Shevchenko VP; Iakovlev VB; Peskov ISh
    Voen Med Zh; 1995 Dec; (12):24-7. PubMed ID: 8779161
    [No Abstract]   [Full Text] [Related]  

  • 14. Platelets, coagulation and fibrinolysis in diabetic and non-diabetic patients with quiescent coronary heart disease.
    Badawi H; el-Sawy M; Mikhail M; Nomeir AM; Tewfik S
    Angiology; 1970 Sep; 21(8):511-9. PubMed ID: 5507352
    [No Abstract]   [Full Text] [Related]  

  • 15. Factors associated with the presence of circulating active tissue factor and activated factor XI in stable angina patients.
    Ząbczyk M; Butenas S; Plicner D; Fijorek K; Sadowski J; Undas A
    Blood Coagul Fibrinolysis; 2012 Apr; 23(3):189-94. PubMed ID: 22343680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Significant undertreatment of high cholesterol level in ischemic heart disease].
    Berglund U; Karlsson E
    Lakartidningen; 2000 Jan; 97(3):155-7. PubMed ID: 10687344
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Leukotriene inhibitors in cardiological practice].
    Trybrat TA
    Lik Sprava; 1997; (3):117-9. PubMed ID: 9377329
    [No Abstract]   [Full Text] [Related]  

  • 18. [Asymptomatic ischemic heart dysfunction, echocardiographic changes and NT-proBNP during 2-years observation].
    Skrzypek A; Nessler J
    Przegl Lek; 2014; 71(7):378-83. PubMed ID: 25338333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Circadian variation in ischemic threshold in patients with stable angina: relation to plasma endothelin-1.
    Li JJ; Huang CX; Fang CH; Chen F; Jiang H; Tang QZ; Li GS
    Angiology; 2002; 53(4):409-13. PubMed ID: 12143945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Hemostasis in ischemic heart disease].
    Lukomskiĭ PE; Liusov VA; Belousov IuB
    Kardiologiia; 1971 Jan; 11(1):5-13. PubMed ID: 5574892
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.